Morris Plains, NJ- April 5, 2012 – SkilaMederi, a leading provider of key opinion leader (KOL) and launch management solutions using software and social network analytics serving the life science industry, is pleased to announce the appointment of Kilian Weiss as Chief Executive Officer (CEO) and Dr. Dick Nichol as Chairman of the Board. Drew McCartney, former CEO of SkilaMederi, will continue to remain on the Board and will focus on his role as an operating partner at BelHealth Investment Partners.
Harold S. Blue, Managing Partner of BelHealth Investment Partners L.P. (BelHealth), and former Chairman of the Board of SkilaMederi, said „Kilian is one of the pioneers of the use of social analytics in the pharmaceutical industry and has a deep understanding of what the market needs. He is also the single largest shareholder of SkilaMederi. I am confident that with this appointment, the company has the expanded leadership to build on its existing strengths and is well-positioned for rapid growth. In appointing Dr. Nichol as Chairman, the Board has been very impressed with Dr. Nichol“s insight and vision for the company and believes, as Chairman Dr. Nichol can effectively guide Kilian and the rest of the organization to establish SkilaMederi as the de facto standard in product launch management and social analytics solutions.“
Commenting on his appointment as CEO of SkilaMederi, Kilian Weiss said „I am excited to be assuming the role of CEO. SkilaMederi benefits from significant relationships with several of the largest life sciences companies and I look forward to expanding those relationships. This is an exciting period and we have a stellar team to capitalize on our unique positioning in the marketplace.“
„Having spent a significant time on strategy and positioning with Kilian and the rest of the SkilaMederi team over the past four months, I am convinced of great opportunities ahead and I look forward to utilizing my experience in the life sciences industry to guide the team as Chairman,“ said Dr. Dick Nichol.
Drew McCartney said „as the CEO of Skila and as an operating committee member of BelHealth, over the past seven months we have accomplished our interim goal of rebuilding our infrastructure for growth and consummating the merger with Mederi, which is a perfect fit both strategically and tactically. With Kilian at the helm, we look to SkilaMederi as a breakout player in the segment As an active board member, I am thrilled wit the opportunity to mentor Kilian. This move also allows me to direct my focus toward growing and managing healthcare companies as a member of BelHealth“s operating committee.“
Simon Mason, the President of SkilaMederi, said „Social media intelligence is transforming the way business is conducted in Big Pharma. Having spent 15 years at Skila and more than 20 years in the pharmaceutical industry I have never been more positive or excited about what we can now provide to our customers. I am looking forward to working closely with Kilian during this exciting phase.“
About SkilaMederi
SkilaMederi is a leading provider of key opinion leader (KOL) and launch management solutions using software and social network analytics to pharmaceutical companies. Combining unparalleled analytics, crowd sourced knowledge extraction mined from the knowledge of thousands of experts, SkilaMederi help pharmaceutical companies to tap into the value of big data. SkilaMederi collaborates with clients to help them maximize time to market while reducing market uptake and reimbursement risk for brands. SkilaMederi has a global presence with offices in Morris Plains, New Jersey; Frankfurt, Germany; London, U.K.; and Lviv, Ukraine.
To learn more about SkilaMederi please visit www.skila.com and www.mederi.net.
About BelHealth Investment Partners
BelHealth Investment Partners L.P. („BelHealth“) is a private equity buyout fund focused exclusively on the small-cap healthcare industry. BelHealth acquires majority positions in healthcare companies that the BelHealth Team believes are undervalued or undermanaged and would benefit from the vast entrepreneurial and operating experience that BelHealth can deliver. Applying an active, hands-on approach to governance, BelHealth utilizes its experience to drive revenue and profit growth and achieve superior returns for its investors. For more information about BelHealth, please go to its website: www.BelHealth.com.
Contacts
SkilaMederi: Kilian Weiss, +49 69 2424064-0
BelHealth Investment Partners: Inder Tallur 516-626-5675
About SkilaMederi
SkilaMederi is a leading provider of key opinion leader (KOL) and launch management solutions using software and social network analytics to pharmaceutical companies. Combining unparalleled analytics, crowd sourced knowledge extraction mined from the knowledge of thousands of experts, SkilaMederi help pharmaceutical companies to tap into the value of big data. SkilaMederi collaborates with clients to help them maximize time to market while reducing market uptake and reimbursement risk for brands. SkilaMederi has a global presence with offices in Morris Plains, New Jersey; Frankfurt, Germany; London, U.K.; and Lviv, Ukraine.
Kontakt:
Mederi AG (part of SkilaMederi)
Janette Bergmann
Hanauer Landstr. 175-179
60314 Frankfurt
06924240640
http://www.mederi.net
j.bergmann@mederi.net
Pressekontakt:
Mederi AG
Janette Bergmann
Hanauer Landstr. 175-179
60314 Frankfurt
j.bergmann@mederi.net
06924240640
http://www.mederi.net